Treatment of blastomycosis with higher doses of fluconazole

Peter G. Pappas, Robert W. Bradsher, Carol A. Kauffman, Gretchen A. Cloud, Carolynn J. Thomas, G. Douglas Campbell, Stanley W. Chapman, Cheryl L Newman, William E. Dismukes

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


Recent clinical data suggest that fluconazole at daily doses of 200 to 400 mg for at least 6 months is moderately effective therapy for non-life- threatening blastomycosis. To examine the usefulness of higher doses of fluconazole therapy for this disorder, we conducted a multicenter, randomized, open-label study to determine the efficacy and safety of two different daily doses of fluconazole (400 and 800 mg) in the treatment of non-life-threatening blastomycosis. Of 39 patients evaluable for efficacy analysis, 34 (87%) were successfully treated, including 89% and 85% of patients who received 400 and 800 mg, respectively. Five (83%) of six patients for whom prior antifungal therapy had failed were successfully treated. The mean duration of therapy was 8.9 months for successfully treated patients. Nineteen patients (48%) reported adverse events, although most were minor. We conclude that fluconazole at daily doses of 400 to 800 mg for at least 6 months is effective therapy for non-life-threatening blastomycosis.

Original languageEnglish (US)
Pages (from-to)200-205
Number of pages6
JournalClinical Infectious Diseases
Issue number2
StatePublished - 1997
Externally publishedYes

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Treatment of blastomycosis with higher doses of fluconazole'. Together they form a unique fingerprint.

Cite this